Trial Profile
A Prospective, Open-Label, Non-Randomized, Multi-Center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Voriconazole (Primary) ; Voriconazole (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Adverse reactions
- Sponsors Pfizer
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 15/05/2013), according to European Clinical Trials Database record.
- 20 Dec 2021 This trial has been completed in Hungary (Global end date: 15 May 2013)
- 18 Oct 2016 New trial record